Buy 4-HO-MiPT for sale online from USA vendor
Table of Contents
-
Introduction
- Overview of 4-HO-MiPT
- Classification as a Psychedelic Tryptamine
-
Chemistry
- Structure of 4-HO-MiPT
- Relation to Other Psychedelic Tryptamines
-
Pharmacology
- Serotonergic Psychedelic Properties
- Dosage Information
-
Subjective Effects
- Physical Effects
- Visual Effects
- Cognitive Effects
- Auditory and Multi-sensory Effects
- Transpersonal Effects
-
Combination Effects
- Interactions with Cannabis, Dissociatives, Benzodiazepines, and Psychedelics
-
Toxicity and Harm Potential
- Lack of Scientific Study
- Harm Reduction Practices
- Tolerance and Addiction Potential
- Dangerous Interactions
-
Legal Status
- Brazil
- Germany
- Japan
- Poland
- Sweden
- Switzerland
- United Kingdom
- United States
-
FAQ (Frequently Asked Questions)
Unveiling the Mysteries of 4-HO-MiPT
4-Hydroxy-N-methyl-N-isopropyltryptamine, also known as 4-HO-MiPT or Miprocin, stands as a distinctive psychedelic substance within the tryptamine class. Its administration induces psychedelic effects reminiscent of psilocybin, aligning it with other members of the psychedelic substituted tryptamines family, including 4-AcO-DMT, 4-HO-MET, and 4-HO-DiPT. These compounds are recognized for producing variations of the core psychedelic effects associated with psilocin.
A Brief History and Human Trials
This relatively uncommon substance has a concise history of human use, with notable attention from Alexander Shulgin in 1979. Shulgin's evaluation, involving a trial with a 12mg dosage, described the experience as richly insightful and highly erotic. Further details about 4-HO-MiPT can be found in Shulgin's 1997 book, TiHKAL. Shulgin's trials and anecdotal reports suggest that 4-HO-MiPT shares similarities with psilocin, the active component in psilocybin mushrooms.
Limited Knowledge on Pharmacology, Metabolism, and Toxicity
Despite its intriguing properties, very little data exists regarding the pharmacological properties, metabolism, and toxicity of 4-HO-MiPT in humans. Similar to psilocin, there have been no reported deaths associated with 4-HO-MiPT use, even in cases where individuals have exceeded the active dose. This implies a high physiological tolerance to the substance.
Present-Day Usage and Distribution
In contemporary times, 4-HO-MiPT finds application both recreationally and as an entheogenic substance. It is commonly distributed as a grey-area research chemical through online vendors. The dual nature of its use raises questions about its potential therapeutic applications and the importance of further research to unravel its full spectrum of effects and safety profile. As interest in psychedelic substances continues to grow, the exploration of 4-HO-MiPT may contribute valuable insights into the fascinating world of psychedelic pharmacology.
History and Culture
The inaugural synthesis of 4-HO-MiPT emerged in 1981, orchestrated by a team of chemists under the leadership of David Repke. This collaborative effort with Alexander Shulgin resulted in a paper exploring the effects of diverse oxygen substituents on the MiPT structure. Among the compounds studied, 4-HO-MiPT stood out as the most intriguing, uniquely possessing classical hallucinogenic effects.
Chemistry
Decoding the Tryptamine Molecule
4-HO-MiPT, also known as 4-hydroxy-N-methyl-N-isopropyltryptamine, belongs to the synthetic indole alkaloid molecules of the tryptamine class. Tryptamines share a fundamental structure comprising a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. The distinct feature of 4-HO-MiPT lies in the substitution at R4 of its indole heterocycle with a hydroxyl (HO) functional group OH-. Additionally, it incorporates a methyl group and an isopropyl chain bound to the terminal amine RN of its tryptamine backbone (MiPT). Essentially, 4-HO-MiPT stands as the N-substituted isopropyl homologue of 4-HO-DMT (Psilocin).
Pharmacology
Unraveling the Psychedelic Effects
The psychedelic effects attributed to 4-HO-MiPT are thought to emanate from its efficacy at the 5-HT2A receptor as a partial agonist. Despite this understanding, the precise nature of these interactions and how they contribute to the psychedelic experience remains elusive. Categorized as a serotonergic psychedelic, 4-HO-MiPT is believed to induce its effects through partial agonism of both 5-HT2A and 5-HT1A serotonin receptors.
Dosage Guidelines
Understanding the dosage spectrum is crucial for safe and informed use of 4-HO-MiPT:
- Threshold: 5 mg
- Light: 10 - 15 mg
- Common: 15 - 25 mg
- Strong: 25 - 35 mg
- Heavy: 35 mg +
These dosage categories provide a framework for users to navigate the intensity of their 4-HO-MiPT experience, emphasizing the importance of responsible usage within the recommended thresholds.
Subjective Effects of 4-HO-MiPT
Disclaimer: Exploring the Anecdotal Realm
The subjective effects of 4-HO-MiPT are delved into through the Subjective Effect Index (SEI), a compilation based on anecdotal user reports and analyses by PsychonautWiki contributors. It's crucial to approach these insights with a dose of skepticism, given their origin.
It's also pertinent to note that the occurrence of these effects is not necessarily predictable or reliable. Higher doses increase the likelihood of experiencing the full spectrum of effects, with adverse effects becoming more probable and potentially including addiction, severe injury, or death.
Physical Effects
-
Sedation & Stimulation: 4-HO-MiPT is recognized for its paradoxical nature, inducing relaxation, stoning, and mild sedation while simultaneously providing a marked sense of physical stimulation—distinct from substances like psilocybin mushrooms or 4-AcO-DMT.
-
Spontaneous Physical Sensations: Users describe a pleasurable, warm, soft, and all-encompassing tingling sensation, intensifying steadily following onset and reaching its peak during the experience.
-
Changes in Felt Bodily Form: Often accompanied by a sense of warmth or psychophysical unity, users may feel physically part of or conjoined with objects in a seamless continuity, manifesting as comfort, tranquility, mindfulness, or bodily tension.
-
Changes in Felt Gravity
-
Pain Relief: Different from opioid-induced relief, this effect appears linked to changes in body perception rather than direct pain suppression.
-
Nausea: Can be mitigated with an empty stomach, with recommendations for fasting or a light meal 3 to 4 hours before ingestion. Generally considered less prominent than with psilocybin mushrooms.
-
Temperature Regulation Suppression: Causes fluctuations in internal temperature perception, necessitating a climate-controllable environment.
-
Muscle Contractions: Transient and benign, distinct from other tryptamines, phenethylamines, and lysergamides.
-
Olfactory Hallucination
-
Frequent Urination
-
Pupil Dilation
-
Increased Salivation
-
Excessive Yawning: Pronounced, especially compared to other substances like LSD.
-
Watery Eyes
-
Teeth Grinding: Less intense than substances like MDMA, but more frequent than with psilocin or psilocybin.
-
Seizure: A rare effect, potentially predisposed to those in physically taxing conditions.
Visual Effects
-
Enhancements
- Colour Enhancement
- Pattern Recognition Enhancement
- Visual Acuity Enhancement
-
Distortions
- Drifting (Melting, Breathing, Morphing, Flowing)
- Colour Shifting
- Depth Perception Distortions
- Perspective Distortions
- Symmetrical Texture Repetition
- Tracers
- After Images
- Brightness Alteration
- Diffraction
- Geometry: Resembles psilocin, ayahuasca, and 2C-E more than LSD or 2C-B, with a natural feel and intricate, abstract, and organic visuals.
-
Hallucinatory States
-
Machinescapes
-
Transformations
-
Internal Hallucination: Lucid, interactive, new experiences, geometry-based, and often of personal, spiritual, or transcendental nature.
-
External Hallucination: Common in dark environments, resembling internal hallucinations in style and theme.
-
Cognitive Effects
The cognitive effects of 4-HO-MiPT are described by many as extremely relaxing, profound, and stoning in style when compared to other commonly used psychedelics such as LSD or 2C-B, which tend to be energetic and stimulating. It contains a large number of typical and unique psychedelic cognitive effects.
- Analysis Enhancement
- Conceptual Thinking
- Autonomous Voice Communication
- Déjà Vu
- Emotion Enhancement
- Enhancement and Suppression Cycles: Constant waves of stimulated thinking and profound ideas, cyclically interspersed with waves of thought suppression and mental intoxication every 20-60 minutes.
- Cognitive Euphoria
- Increased Libido
- Immersion Enhancement
- Novelty Enhancement
- Creativity Enhancement
- Feelings of Impending Doom
- Catharsis
- Rejuvenation
- Increased Sense of Humor
- Laughter Fits
- Increased Music Appreciation
- Memory Suppression
- Ego Death
- Personal Bias Suppression
- Thought Connectivity
- Thought Loops
- Confusion
- Delusion
- Time Distortion
- Wakefulness
Auditory Effects
- Auditory Enhancement
- Auditory Distortion
- Auditory Hallucination
Multi-sensory Effects
- Synaesthesia: Rare and non-reproducible; more likely at higher doses, especially among those predisposed to synaesthetic states.
Transpersonal Effects
It should be noted that these effects are reported to occur less reliably and impactfully than with the closely related psilocin or psilocybin and generally require heavier doses to potentially induce.
- Spirituality Enhancement
- Existential Self-realization
- Unity and Interconnectedness
Combination Effects with 4-HO-MiPT
Disclaimer: The information provided on combination effects is based on anecdotal user reports and subjective experiences. Caution is advised, and individual reactions may vary.
Cannabis
Amplification of Sensory and Cognitive Effects
Combining cannabis with 4-HO-MiPT can lead to a substantial amplification of both sensory and cognitive effects. Users should approach this combination with extreme caution, particularly if they are not experienced with psychedelics. It is essential to note that this interaction may intensify anxiety, confusion, and delusion aspects of cannabis significantly. To mitigate risks, those opting for this combination are advised to start with a fraction of their usual cannabis dose and reduce their normal intake pace.
Dissociatives
Enhancement of Geometry, Euphoria, and Hallucinatory Effects
Dissociatives, when combined with 4-HO-MiPT, have the potential to enhance geometric patterns, euphoria, dissociation, and hallucinatory effects. The interaction may result in more vivid visuals than dissociatives alone, along with intensified internal hallucinations, confusion, nausea, delusions, and an increased risk of a psychotic reaction. Users should exercise caution and be aware of the potential for an intensified experience.
Benzodiazepines
Reduction of Intensity with Potential Consequences
Depending on the dosage, benzodiazepines can slightly to completely reduce the intensity of the cognitive, physical, and visual effects of a 4-HO-MiPT trip. While they can be effective in mitigating a bad trip, caution is advised due to the high addiction potential associated with benzodiazepines. Acquiring benzodiazepines for this purpose should be approached carefully, considering the trade-off between reduced trip intensity and potential consequences, such as amnesia.
Psychedelics
Intensification and Synergistic Effects
When combined with other psychedelics, the physical, cognitive, and visual effects of each substance intensify and synergize strongly with each other. However, the synergy between these substances is unpredictable and generally not advised due to the potential for heightened and unpredictable experiences. If individuals choose to combine psychedelics, it is recommended to start with lower dosages than they would take for either substance individually to mitigate risks.
Experience Reports
While the combination effects outlined above provide insights, individual experiences may vary. Users are encouraged to exercise caution, start with lower doses, and prioritize safety when exploring combinations with 4-HO-MiPT.
Toxicity and Harm Potential of 4-HO-MiPT
Lack of Scientific Study
The toxicity and long-term health effects of recreational 4-HO-MiPT use remain largely unstudied within a scientific context, and the exact toxic dose remains unknown. This is primarily because 4-HO-MiPT is categorized as a research chemical with minimal history of human usage.
Anecdotal Evidence
Anecdotal evidence from individuals who have experimented with 4-HO-MiPT suggests that trying the drug by itself at low to moderate doses, used sparingly, does not appear to result in negative health effects. However, it is crucial to note that no guarantees can be made regarding individual reactions, emphasizing the necessity for independent research to ensure the safety of substance combinations before consumption.
Harm Reduction Practices
It is strongly recommended that harm reduction practices be employed when using 4-HO-MiPT. This includes thorough research, cautious dosing, and a mindful approach to substance combinations to minimize potential risks and adverse effects.
Tolerance and Addiction Potential
4-HO-MiPT is reported as non-habit-forming, and in many cases, the desire to use it can decrease with continued use. It is often described as self-regulating, suggesting that users may naturally regulate their intake.
Tolerance to 4-HO-MiPT effects develops almost immediately after ingestion, with approximately 3 days required for tolerance reduction to half and 7 days for a return to baseline (in the absence of further consumption). Notably, 4-HO-MiPT exhibits cross-tolerance with all psychedelics, meaning the consumption of 4-HO-MiPT can reduce the effects of other psychedelics.
Dangerous Interactions
Warning: Many psychoactive substances that are reasonably safe on their own can become dangerous or even life-threatening when combined with certain other substances. Always conduct independent research to ensure safety.
Known Dangerous Interactions
-
Lithium: Combining lithium, often prescribed for bipolar disorder, with psychedelics like 4-HO-MiPT significantly increases the risk of psychosis and seizures, making this combination strictly discouraged.
-
Cannabis: Cannabis may exhibit unexpectedly strong and unpredictable synergy with 4-HO-MiPT, elevating the risk of adverse psychological reactions such as anxiety, paranoia, panic attacks, and psychosis. Caution is advised, and users are encouraged to start with a fraction of their normal cannabis dose.
-
Stimulants: Combining 4-HO-MiPT with stimulants like amphetamine, cocaine, or methylphenidate can heighten the risk of anxiety, paranoia, panic attacks, and thought loops. This interaction may also elevate the risk of mania and psychosis.
-
Tramadol: Tramadol, known to lower the seizure threshold, combined with psychedelics like 4-HO-MiPT may act to trigger seizures in susceptible individuals.
Note: The list of dangerous interactions is not exhaustive, and users are advised to conduct thorough independent research for a comprehensive understanding of potential risks.
Legal Status in Various Countries
Brazil
As of August 21, 2018, Brazil took regulatory action by adding 4-HO-MiPT to Portaria SVS/MS nº 344. The possession, distribution, and use of this substance are now considered illegal in the country.
Germany
In Germany, 4-HO-MiPT falls under the purview of the NpSG (New Psychoactive Substances Act) as of July 18, 2019. The production and import with the intention to place it on the market, administration to another person, placing it on the market, and trading are all punishable offenses. While possession is illegal, it is not punishable. There is a possibility that orders of 4-HO-MiPT could be deemed punishable as an incitement to place it on the market.
Japan
Effective March 25th, 2015, 4-HO-MiPT is a controlled substance in Japan, making its possession, distribution, and use illegal in the country.
Poland
Poland classifies 4-HO-MiPT as a New Psychoactive Substance (NPS) class drug, rendering it illegal to possess or distribute within the country.
Sweden
As of November 1, 2005, 4-HO-MiPT is categorized as a health hazard under the "Act on the Prohibition of Certain Goods Dangerous to Health" in Sweden. This classification makes it illegal to sell or possess the substance.
Switzerland
Switzerland has listed 4-HO-MiPT as a controlled substance under Verzeichnis E, indicating its illegal status in the country.
United Kingdom
In the United Kingdom, 4-HO-MiPT is designated as a Class A drug due to the tryptamine catch-all clause, making its possession, distribution, and use illegal.
United States
As of now, 4-HO-MiPT remains unscheduled in the United States. However, it may be considered an analogue of psilocin (4-HO-DMT), a Schedule I drug under the Controlled Substances Act. Consequently, the sale for human consumption or the use for illicit non-medical or industrial purposes could lead to legal prosecution under the Federal Analogue Act. Individuals should be aware of the legal implications associated with this substance in the United States.
FAQ (Frequently Asked Questions)
1. Is 4-HO-MiPT habit-forming?
No, 4-HO-MiPT is generally reported as non-habit-forming, and users may experience a decrease in the desire to use it over time.
2. What is the recommended harm reduction practice for using 4-HO-MiPT?
It is strongly recommended to practice harm reduction by conducting thorough research, cautious dosing, and avoiding combinations with other substances without proper knowledge of potential interactions.
3. How long does it take for tolerance to 4-HO-MiPT to diminish?
Tolerance to 4-HO-MiPT develops almost immediately after ingestion. It takes about 3 days for the tolerance to be reduced to half and 7 days to return to baseline in the absence of further consumption.
4. What are the legal implications of 4-HO-MiPT in the United States?
As of now, 4-HO-MiPT is unscheduled in the United States. However, it may be considered an analogue of psilocin, a Schedule I drug, making certain activities, such as sale for human consumption, potentially prosecutable under the Federal Analogue Act.
5. How does 4-HO-MiPT interact with cannabis?
Combining 4-HO-MiPT with cannabis can amplify the sensory and cognitive effects. Caution is advised, and users are recommended to start with a fraction of their normal cannabis dose to avoid unintended adverse reactions like anxiety or paranoia.
Please note that these FAQs provide general information and users are encouraged to seek professional advice and conduct thorough research for their specific circumstances.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics